Skip to content
Search

Latest Stories

PSNC: DHSC, NHSE must pause rollout of new services, including contraception service for pharmacies

The Pharmaceutical Services Negotiating Committee (PSNC) has asked NHS England to stop directing more patients to community pharmacies until extra funding is injected in the sector.

“Any new or expanded services or Pharmacy Quality Scheme in 2023/24 must not be roll out by NHS England and Department of Health and Social Care (DHSC) unless extra funding is put into community pharmacies, the PSNC has told Ministers.


It also suggested that the DHSC should consider putting caps on existing Advanced Services to protect core dispensing funding.

The committee has stressed again that without an urgent injection of extra funding there is not enough money to pay for the current services and dispensing being done by the sector; let alone for new things to be rolled out.

It has urged: “Instead, the focus needs to be on supporting community pharmacies to meet the day-to-day needs of patients and on building on the advice that we already offer to the public via a fully-funded Pharmacy First scheme.”

“If they do not put additional funding into pharmacies they will be presiding over the collapse of the community pharmacy sector and of safe medicines supply,” warned PSNC.

“In addition to extra funding, they must make good their commitments to supporting efficiencies within the sector and make progress on regulatory easements that would allow greater flexibility to all pharmacy owners, reducing bureaucracy and costs.”

The committee told Ministers that they need to decide what sort of community pharmacy network they want: businesses are failing and this will imminently put medicines supply at risk.

It is continuing to argue that a fully-funded Pharmacy First service would be a good route to get additional funding into the sector quickly, while also delivering on Government’s ambitions and supporting patients and its wider primary care colleagues.

“We are pressing hard to ensure that this is included in the Government’s upcoming Primary Care Recovery Plan. Without this or another funding lifeline, they can expect further primary care crises ahead as pharmacy businesses continue to fail.”

Janet Morrison, PSNC Chief Executive, said: “Our position is very clear: pharmacy businesses are on the brink of collapse so it makes no sense whatsoever to add any further services or requirements for 2023/24 without additional funding.  The Government simply has not put enough money into the contract and there isn’t the capacity within the sector to deliver them.”

“The question Ministers now face about the investment needed to deliver Pharmacy First is not whether they can afford it, but whether they can afford not to do it.

Morrison has once again warned Ministers about how desperate things have become. She informed them that many businesses are now operating at a loss, struggling with drug pricing, staffing, increasing public demand and staying open.

She said: “We are struggling to keep our lights on and urgently need investment. DHSC and NHSE need to decide what sort of a pharmacy sector they want in the future: do they want to build on our success during the pandemic and deliver the Prime Minister’s vision for a community pharmacy sector playing a greater role in primary care, or do they want to preside over the decimation of the sector as we know it?

“And we have today told DHSC and NHSE that they must pause the rollout of new services, including the much-anticipated contraception service, and 2023/24 Pharmacy Quality Scheme because we don’t believe pharmacy owners have the capacity under current conditions to properly undertake this work.

Government and the NHS have all the evidence they need to show them that without urgent action they – and the public – will lose significant parts of the community pharmacy sector, and soon. This would be catastrophic for pharmacy, patients and for primary care and we are doing everything within our power to prevent it from happening.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less